Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus

To report phase 1 bioequivalence results comparing MYL‐1501D, US reference insulin glargine (US IG), and European reference insulin glargine (EU IG).

• Publication year

  2019

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2019-11-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.13919PMID 31724253PMCID 7079113
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Implementation of a Health Plan Program for Switching From Analogue to Human Insulin and Glycemic Control Among Medicare Beneficiaries With Type 2 Diabetes

  2019cited by this paper
• Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus

  2019cited by this paper
• Efficacy and safety of MYL‐1501D versus insulin glargine in people with type 1 diabetes mellitus: Results of the INSTRIDE 3 phase 3 switch study

  2019cited by this paper
• Insulin Analogues for Type 2 Diabetes.

  2019cited by this paper
• Review for "Efficacy and Safety of MYL‐1501D Versus Insulin Glargine in Patients With Type 1 Diabetes Mellitus: Results of the INSTRIDE 3 Phase 3 Switch Study"

  2019cited by this paper
• Author response for "Efficacy and Safety of MYL‐1501D Versus Insulin Glargine in Patients With Type 1 Diabetes Mellitus: Results of the INSTRIDE 3 Phase 3 Switch Study"

  2019cited by this paper
• Efficacy and safety of MYL‐1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study

  2018cited by this paper
• Efficacy and safety of MYL‐1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study

  2018cited by this paper
• Long-acting insulin analogues for type 1 diabetes: An overview of systematic reviews and meta-analysis of randomized controlled trials

  2018cited by this paper
• LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels

  2017cited by this paper
• Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects

  2017influential reference
• Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes

  2016cited by this paper
• Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

  2016cited by this paper
• How to Accurately Establish Pharmacokinetics/Pharmacodynamics of Long-Acting Insulins in Humans: Relevance to Biosimilar Insulins

  2015cited by this paper
• Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

  2015cited by this paper
• Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis

  2014cited by this paper
• Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues

  2013cited by this paper
• The economics of biosimilars.

  2013cited by this paper
• Standards of Medical Care in Diabetes—2014

  2013cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

  2012influential reference
• Standards of Medical Care in Diabetes—2012

  2011cited by this paper
• Pharmacokinetics and pharmacodynamics of basal insulins.

  2011cited by this paper
• Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.

  2010cited by this paper
• Regulatory Considerations in Approval on Follow‐on Protein Drug Products

  2010cited by this paper
• The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back

  2008cited by this paper
• The challenge of biosimilars.

  2008cited by this paper
• AIR Inhaled Insulin Versus Subcutaneous Insulin

  2008cited by this paper
• Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.

  2005cited by this paper

• Trends in baseline HbA1c and body-mass index in randomised trials of people with type 1 diabetes from 1993 to 2025: an IMI2 SOPHIA systematic review and meta-analysis

  2025cites this paper
• Biosimilar insulins: Narrative review of the regulatory framework and registration studies

  2025cites this paper
• Absence of a glucose‐lowering effect in glucose clamp procedures with a long‐acting insulin analogue

  2024cites this paper
• Pharmacokinetic and pharmacodynamic bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU‐ und US‐sourced reference insulins

  2023cites this paper
• Biosimilar of analogue of insulin glargin: proven safety, effectiveness, interchangeability

  2023cites this paper
• Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US‐licensed Humulin® N formulation in healthy subjects: Results from the RHINE‐2 (Recombinant Human INsulin Equivalence‐2) study

  2023cites this paper
• Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and Lantus® in healthy subjects: Pharmacokinetic parameters of both parent insulin glargine and M1 were used as endpoints

  2022cites this paper
• Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar Insulin‐R with the US‐licensed Humulin® R formulation in healthy subjects: Results from the RHINE‐1 (Recombinant Human INsulin Equivalence‐1) study

  2022cites this paper
• How to Achieve Sufficient Endogenous Insulin Suppression in Euglycemic Clamps Assessing the Pharmacokinetics and Pharmacodynamics of Long-Acting Insulin Preparations Employing Healthy Volunteers

  2022cites this paper
• Pharmacokinetic and pharmacodynamic bioequivalence between regular human insulin (rDNA origin) in 0.9% sodium chloride ready‐to‐use infusion 1 U/mL and 100 U/mL concentrate diluted to 1 U/mL in healthy males

  2021cites this paper
• MYL1501D Insulin Glargine: A Review in Diabetes Mellitus

  2020cites this paper
• Pharmacokinetic and pharmacodynamic bioequivalence of proposed biosimilar MYL‐1501D with US and European insulin glargine formulations in patients with type 1 diabetes mellitus

  2019cites this paper
• Single‐dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK‐1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects

  2017cites this paper